Meningococcal class 1 outer-membrane protein vaccine

Details Meningococcal class 1 outer-membrane protein vaccine Meningococcal class 1 outer-membrane protein vaccine

2006-10-10

2006-10-10

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S234100, C424S190100, C424S184100, C424S197110, C424S194100, C530S350000, C530S300000, C530S825000, C530S807000, C530S806000

Reexamination Certificate

active

07118757

ABSTRACT:
Outer-membrane vesicles, Class 1 outer membrane proteins ofNeisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease.

REFERENCES:
patent: 4271147 (1981-06-01), Helting
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4459286 (1984-07-01), Hilleman et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4673574 (1987-06-01), Anderson
patent: 4695624 (1987-09-01), Marburg et al.
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 4711779 (1987-12-01), Porro et al.
patent: 4761283 (1988-08-01), Anderson
patent: 4762713 (1988-08-01), Anderson
patent: 4830852 (1989-05-01), Marburg et al.
patent: 4882317 (1989-11-01), Marburg et al.
patent: 5034519 (1991-07-01), Beuvery et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5312620 (1994-05-01), Ribi
patent: 5356778 (1994-10-01), Hansen et al.
patent: 5736361 (1998-04-01), Carbonetti et al.
patent: 5747287 (1998-05-01), Blake et al.
patent: 5766914 (1998-06-01), Deits
patent: 6348332 (2002-02-01), Carbonetti et al.
patent: 1030443 (1989-01-01), None
patent: 048023 (1982-03-01), None
patent: 0090660 (1983-10-01), None
patent: 0145359 (1985-06-01), None
patent: 0182401 (1986-05-01), None
patent: 0 208 375 (1987-01-01), None
patent: 0301992 (1989-02-01), None
patent: 64029321 (1989-01-01), None
patent: WO 89/04873 (1989-06-01), None
patent: WO 89/10967 (1989-11-01), None
Bessler et al Immunobiol 170: 239-244, 1985 Specific Antibodies Elicited by Antigen Covalently Linked to a Synthetic Adjuvant.
Lerner Nature 299: 592-596, Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity.
Teerink et al. J. Exp. Med. 166: 63-76, 1987.
Wetzler et al. Trans. Assoc. Am. Physicians CII: 78-90, 1989.
Runeberg-Nyman et al. In: Keystone Symposium on Protein Folding, Structure and Function, CO, USA, Apr., 8-14, 1991, abstract.
Chattopadhyay et al. In: Proc. European Congr. Biotechnol. 5 Meeting, Copenhagen, Jul. 8-13, 1990, abstract.
Laitinen K. NPHI, A1/1988, Helsinki, 57-62 (relevant pages), 1988.
Poolman et al. Dev. Biol. Stand. 63: 147-152, S. Karger, Basel, 1986.
Wahlstrom et al. In: Neisseriae 1990 (Ed) Achtman et al. Walter de Gruyter & Co., Berlin, pp. 307-312, 1991.
Sigma 1987 Catalog of Biochemical and Organic Compounds for research and Diagnsotic Clinical Reagents. pp. 196-200, 1987.
Abdillahi et al. Microb. Pathogen. 4: 27-32, 1988.
Palker et al. PNAS 85: 1932-1936, Mar. 1988.
Barlow et al. In: Proceedings of the Symposium, 110th Meeting of the Society for General Microbiology, University of Southampton (UK), Jan. 6-8, 1988.
Lowell et al Journal of Exper. Med 167:658-663, 1988.
Makela et al (Seminars in Inf. Dis., vol. IV: Bacterial Vaccines, 1982, p. 360-365.
Newton et al Science 244: 70-72 Apr. 1989.
Poolman et al I & I 40:398-406 1983.
Frasch et al vol. IV: Bacterial Vaccines, 1982 pp. 263-267.
Wiertz et al Cell Biochem Suppl 326 Jan. 1984.
Lynch et al J. Biophysical Soc. 104-107, 1984.
Porro M. In: Towards Better Carbohydrate Vaccines. (Ed) Bell et al. John Wiley & Sons, New York, pp. 279-306, 1987.
Gotschlich et al. PNAS 84: 8135-8139, 1987.
Carbonetti et al. PNAS 85: 6841-6845, 1987.
McGuinness et al. Lancet 337: 514-517, 1991.
Frasch et al. Clin. Invest. Med. 9: 101-107, 1986.
Beuvery et al. Medecine Tropicale 43: 123-127, 1983.
Frasch CE. Clin. Microbiol. Rev. 2: S134-S138, Apr. 1989.
Bernatowitz et al. Anal. Biochem. 155: 95-102, 1986.
IM Kramer et al. In: The Pathogenic Neisseriae, Proceedings of the Fourth International Symposium, Asilomar, California, Oct. 21-25, American Society for Microbiology, Washington, D.C., pp. 611-615, 1985.
Sukkonen et al Microbial Pathogenesis 3:261-267, 1987.
Mandrell et al Infect. & Immunity 57: 1590-1598, 1989.
Hirama Immunological Method vol. III, Chapter 3, p. 52.
Beuvery, E.C. et al., Infect. Immun. 40:369-390 (1983).
Jiskoot, W. et al., Infect. Immun. 54:333-338 (1986).
Wang, L.Y. and Frasche, C.E., Infect. Immun. 46:408-414 (1984).
Teerlink, T. et al., Vaccine 5:307-314 (1987).
Gregoriadis, G. et al., Vaccine, 5:145-151 (1987).
Tsai, C.M. and Frasch, C.E., J. Bacteriol. 141:169-176 (1980).
Tsai, C.M. et al., Chem. Abstr. 94:, abstract 2051112.
Barlow, A.K. et al., Infect. Immun. 55:2735-2740 (1987).
Wedege, E. et al., J. Immunol. Methods, 113:51-59 (1988).
Barlow, A.K. et al., Molecular Microbiology, 3(2): 131-139 (1989).
International Search Report from PCT Application No. 89/05678 (Publication No. WO90/06696), which was filed Dec. 19, 1989.
European Patent No. 0,351,604 (Jan. 24, 1990).
European Patent No. 0,109,688 (May 30, 1984).
European Patent No. 0,372,501 (Jun. 13, 1990), considered only to extent of Applicants ZDS Document not translated.
European Patent No. 0,011,243 (May. 28, 1980).
Abdillahi and Poolman, Biological Abstracts 87:115445 (1989).
Poolman, J.T. et al., Infect. Immun. 57:1005-1007 (1989).
Wedege, E. and L. Oddvar Frohølm, “Human Antibody Response to a Group B Serotype 2a Meningococcal Vaccine Determined by Immunoblotting,”Infection and Immunity, 51 (2) :571-578 (1986).
Frasch, C.E., et al., “Immune Responses of Adults and Children to Group BNeisseria meningitidisOuter Membrane Protein Vaccines,”Bacterial Vaccines, 262-272 (1988).
Beuvery, E.C., et al., “Characteristics of an Alternative Meningococcal Type 15 (P1. 16) Outer Membrane Protein Vaccine,”J. Microbiology, 52:232-235 (1986).
Poolman, J.T., et al., “Comparison of Meningococcal Outer Membrane Protein Vaccines Solubilized with Detergent or C Polysaccharide,”Antonie van Leeuwenhoek, 53:413-419 (1987).
Wiertz, E.J.H.J., et al., “Human T-Cell Epitope Mapping of the Meningococcal Class 1 Outer Membrane Protein,”J. Cell Biochem Suppl. 0(13 Part A) (1989); Abstract C 722.
Abdillahi, Hussein et al., “Definition of Meningococcal Class 1 OMP Subtyping Antigens by Monoclonal Antibodies,”FEMS Microbiology Immunology, vol. 47:139-144 (1988).
West., Susan E.H. et al., “Genetic Loci and Linkage Associations inNeisseria gonorrhoeaeandNeisseria meningitidis,” Clinical Microbiology Reviews, vol. 2, Suppl.:S92-S103 (1989).
Barlow, Ann K. et al., “Molecular Cloning and Expression ofNeisseria meningitidisClass 1 Outer-Membrane Protein inEscherichia coliK-12,”J. Med. Microbiol.vol. 26:180-183 (C) (1988).
Stein, Daniel C., “Introduction of Cloned Genes intoNeisseria gonorrhoeae,” Clinical Microbology Reviews, vol. 2, Suppl.:S146-S149 (1989).
Shinners, Elizabeth N. et al., “Neisseria gonorrhoeaeRecombinant Strains Expressing Hybrid Serological Reactivities of Outer Membrane Proteins IA and IB,”J. Infectious Diseasesvol. 158:529-536 (1988).
Tarkka, Eveliina et al., “Antibody Production to a Meningococcal Outer Membrane Protein Cloned into LiveSalmonella typhimuriumaroA Vaccine Strain,”Microbial Pathogenesis, vol. 6:327-335 (1989).
Tarkka, Eveliina et al., “Cloning of an Outer Membrane Protein ofNeisseria meningitidisinEscherichia coli,” Microbial Pathogenesis, vol. 3:445-453 (1987).

Affiliated with

Also associated with

Rating

Meningococcal class 1 outer-membrane protein vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Meningococcal class 1 outer-membrane protein vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Meningococcal class 1 outer-membrane protein vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3614989